Faculty, Staff and Student Publications

Language

English

Publication Date

1-1-2026

Journal

Clinical Ophthalmology

DOI

10.2147/OPTH.S545641

PMID

41891096

PMCID

PMC13016381

PubMedCentral® Posted Date

2-4-2026

PubMedCentral® Full Text Version

Author MSS

Abstract

Background: Research on metformin, sulfonylureas, and open-angle glaucoma risk in type 2 diabetes mellitus (T2DM) has yielded inconsistent findings. This study examined associations between hypoglycemic treatments and glaucoma diagnosis rates.

Methods: This retrospective cohort study analyzed electronic health records of newly diagnosed T2DM patients from the Merative™ Explorys® Therapeutic Dataset (2010-2022), comparing three groups: metformin monotherapy, sulfonylureas plus metformin combination, and untreated controls. Propensity score matching balanced demographics, glycemic control, body mass index, blood pressure, lipid levels, and comorbidities. Cox proportional hazards models calculated adjusted hazard ratios for incident glaucoma.

Results: After 1:1 propensity score matching, metformin monotherapy (N=100,387) showed a non-significant trend toward higher glaucoma diagnosis rates compared to matched controls (HR 1.106, 95% CI 1.014-1.207, p=0.023; adjusted HR 1.076, 95% CI 0.995-1.163, p=0.067). Patients receiving combination therapy with sulfonylureas and metformin (N=38,692) demonstrated statistically significantly higher glaucoma diagnosis rates relative to matched controls (HR 1.235, 95% CI 1.077-1.417, p=0.002; adjusted HR 1.194, 95% CI 1.075-1.326, p=0.001). Direct comparison between combination therapy and metformin monotherapy did not reach statistical significance (adjusted HR 1.084, 95% CI 0.973-1.207, p=0.144).

Conclusion: This observational study found associations between diabetes medications and increased glaucoma diagnosis rates but cannot establish causality. Multiple competing explanations exist: reverse causation (clinicians preferentially prescribing metformin to diabetic patients with emerging glaucoma based on prior protective literature), confounding by indication (sicker patients requiring medication having inherently higher glaucoma risk), and detection bias (differential surveillance patterns). The non-significant metformin monotherapy finding (p=0.067) aligns with recent meta-analyses showing no association. While the statistically significant combination therapy association warrants investigation, it should not be interpreted as definitive causation. Prospective studies controlling for disease severity, surveillance patterns, and treatment indication are needed to disentangle these explanations and inform clinical practice.

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.